Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bone matrix collagen type I is the predominant organic component of bone extracellular matrix, comprising approximately 90% of the protein content and synthesized primarily by osteoblasts. It forms triple-helical fibrils that provide essential mechanical tensile strength and serve as a scaffold for bone cells, including osteoblasts, osteocytes, and osteoclasts, while facilitating hydroxyapatite mineral deposition for bone rigidity. These fibrils are densely cross-linked and arranged in lamellae with alternating orientations to optimize bone strength and resist stress. Collagen type I interacts dynamically with non-collagenous proteins like osteocalcin, osteopontin, and proteoglycans to regulate fibrillogenesis, mineralization, and remodeling processes essential for bone homeostasis. Mutations or deficiencies in its structure lead to increased fracture risk and disorders such as osteogenesis imperfecta, highlighting its critical role in skeletal integrity. Although not a conventional therapeutic target like receptors or enzymes, its involvement in bone matrix dynamics influences regenerative strategies in tissue engineering.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bone matrix collagen type I.